Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 16, 2020 10:24 ET | Source: Novartis International AG

Novartis reinforces commitment to patient access, pricing a EUR 1.85 billion sustainability-linked bond

First healthcare industry sustainability-linked bond (SLB) further embeds Environmental Social Governance (ESG) targets into the core of Novartis business operations SLB linked to 2025 Patient Access...
September 14, 2020 06:15 ET | Source: Novartis International AG

European Medicines Agency (EMA) approves safety label update for Novartis Beovu®

Novartis worked with the EMA to update the Beovu® (brolucizumab) label to guide physicians in their treatment of wet AMD The update includes the additional characterization of retinal vasculitis...
September 14, 2020 01:15 ET | Source: Novartis International AG

Novartis reports positive topline results from the first Phase III trial of Beovu® versus aflibercept in patients with diabetic macular edema (DME)

In Phase III KITE study, Beovu (brolucizumab) 6 mg achieved its primary endpoint of non-inferiority to aflibercept 2 mg in mean change in best-corrected visual acuity (BCVA) at year one (week...
September 11, 2020 11:05 ET | Source: Novartis International AG

Novartis data show early treatment with Mayzent® (siponimod) delays disability progression and show benefits in cognitive performance in patients with secondary progressive multiple sclerosis (SPMS)

Post hoc EXPAND analysis showed improvements in cognitive processing speed in patients with active and non-active SPMS treated with Mayzent1 Subgroup analyses of the EXPAND trial showed the value of...
September 11, 2020 11:00 ET | Source: Novartis International AG

Novartis presents data at ACTRIMS-ECTRIMS for Kesimpta® (ofatumumab) in newly diagnosed treatment-naïve adults with relapsing multiple sclerosis

New post hoc data from Phase III ASCLEPIOS trials showed newly diagnosed, treatment-naïve patients experienced reductions in annualized relapse rates and MRI lesion activity and demonstrated...
September 08, 2020 01:15 ET | Source: Novartis International AG

Novartis data at ACTRIMS-ECTRIMS highlight the strength of leading multiple sclerosis (MS) portfolio with life-changing therapies for people across the MS spectrum

Novartis will present 48 abstracts from its leading MS portfolio, including new data on recently FDA-approved Kesimpta® (ofatumumab)—the first and only self-administered, targeted B-cell therapy for...
September 07, 2020 01:15 ET | Source: Novartis International AG

Novartis post hoc analysis shows high-dose Enerzair® Breezhaler® reduces asthma exacerbations versus medium-dose, complementing key pivotal IRIDIUM study findings

High-dose, once-daily Enerzair® Breezhaler® [IND/GLY/MF] reduced asthma exacerbation rates by 21% (moderate or severe) and 31% (severe) versus medium-dose, over 52 weeks1 Once-daily Enerzair...
September 01, 2020 01:00 ET | Source: Novartis International AG

Novartis announces ambitious ESG targets to increase access to medicines and achieve full carbon neutrality

2025 target to increase patients reached in LMICs with strategic innovative medicines by 200% and the Novartis Flagship Programs by 50% - bringing potential reach to over 23 million patients across...
August 30, 2020 02:30 ET | Source: Novartis International AG

Novartis new analysis shows high consistency in lowering LDL-C in individual response with investigational inclisiran

Pooled data from Phase III ORION-10 and -11 showed highly consistent efficacy, tolerability and safety profile over 17 months on twice-yearly subcutaneous dosing in 2,300 patients (of which 1,164 were...
August 29, 2020 06:30 ET | Source: Novartis International AG

Novartis announces positive results from Phase II study of LNP023 in patients with paroxysmal nocturnal hemoglobinuria (PNH)

Oral, investigational complement factor B inhibitor LNP023 substantially improved hematological response as add-on therapy to eculizumab Seven of ten patients discontinued eculizumab and remained on...